- Perhaps not surprisingly, Credit Suisse's Baxter (BAX +0.1%) upgrade is in part attributable to the expected three-month delay in FDA approval for Biogen's (BIIB -2.1%) long-lasting factor VIII therapy Eloctate.
- Concerns about looming competition in the hemophilia market have been a thorn in BAX's side over the past several months.
- In hiking his price target to $80 from $73, analyst Bruce Nudell also highlights "BAX's recent enrollment of its own long-acting rFVIII trial" (BAX 855) and points to "the potential for value creation should BAX split its Medical Products & Bioscience segment."
Eloctate delay cited in Credit Suisse Baxter upgrade
Recommended For You
More Trending News
About BAX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
BAX | - | - |
Baxter International Inc. |